The cytoplasmic trafficking of DNA topoisomerase IIα correlates with etoposide resistance in human myeloma cells

Experimental Cell Research

Volumn 295, Issue 2, 2004, Pages 421-431

  Engel, Roxane ^a   Valkov, Nikola I ^a   Gump, Jana L ^a   Hazlehurst, Lori ^a   Dalton, William S ^a   Sullivan, Daniel M ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

BME; BrdU; Bromodeoxyuridine; DNA topoisomerase II ; Drug resistance; FBS; Fetal bovine serum; FITC; Fluorescein isothiocyanate; Leptomycin B; Multiple myeloma; Protein trafficking; Topo; Topoisomerase; TRITC; mercaptoethanol

Indexed keywords

ANTINEOPLASTIC AGENT; BROXURIDINE; CARMUSTINE; CISPLATIN; CYTARABINE; DNA TOPOISOMERASE; DNA TOPOISOMERASE 2ALPHA; DNA TOPOISOMERASE 2BETA; DOUBLE STRANDED DNA; ETOPOSIDE; GYRASE INHIBITOR; LEPTOMYCIN B; MITOXANTRONE; PACLITAXEL; TOPOTECAN; UNCLASSIFIED DRUG;

ARTICLE; CELL COUNT; CELL CYCLE; CELL CYCLE S PHASE; COMPARATIVE STUDY; CORRELATION ANALYSIS; CYTOPLASM; DNA STRAND BREAKAGE; DRUG SENSITIVITY; DRUG UPTAKE; GAMMA IRRADIATION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN DNA BINDING; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

BOVINAE;

EID: 1842829000     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2004.01.012     Document Type: Article

References (43)

1. Champoux J.J. DNA topoisomerases: structure, function, and mechanism. Annu. Rev. Biochem. 70:2001;369-413.
2. Wang J.C. Cellular roles of DNA topoisomerases: a molecular perspective. Nat. Rev., Mol. Cell Biol. 6:2002;430-440.
3. Wang J.C. DNA topoisomerases. Annu. Rev. Biochem. 65:1996;635-692.
4. Nitiss J.L. Investigating the biological functions of DNA topoisomerases in eukaryotic cells. Biochim. Biophys. Acta. 1400:1998;63-81.
5. Drake F.H., Zimmerman J.P., McCabe F.L., Bares H.F., Per S.R., Sullivan D.M., Ross W.E., Mattern M.R., Johnson R.K., Crooke S.T., Mirabelli C.K. Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme. J. Biol. Chem. 262:1987;16739-16747.
6. Heck M.M., Earnshaw W.C. Topoisomerase II: a specific marker for cell proliferation. J. Cell Biol. 103:1986;2569-2581.
7. Burden D.A., Goldsmith L.J., Sullivan D.M. Cell-cycle dependent phosphorylation and activity of Chinese hamster ovary topoisomerase II. Biochem. J. 293:1993;297-304.
8. Woessner R.D., Mattern M.R., Mirabelli C.K., Johnson R.K., Drake F.H. Proliferation and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ. 2:1991;209-214.
9. Turley H., Comley M., Houlbrook S., Nozaki N., Kikuchi A., Hickson I.D., Gatter K., Harris A.L. The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues. Br. J. Cancer. 75:1997;1340-1346.
10. Sinha B.K. Topoisomerase inhibitors: a review of their therapeutic potential in cancer. Drugs. 49:1995;11-19.
11. Hande K.R. Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim. Biophys. Acta. 1400:1998;173-184.
12. Bhalla K., Gerson S., Grant S.S., Sullivan D.M. Pharmacology and molecular mechanism of action or resistance of antineoplastic agents: current status and future potential. Hoffman R., Benz E.J., Shattil S.J., Furie B., Cohen H.J., Silberstein L.E., McGlave P. Hematology: Basic Principles and Practice. 2000;885-938 Churchill Livingstone, New York, NY.
13. Engel R., Valkov N.I., Sullivan D.M. Drug resistance to DNA topoisomerase I and II inhibitors. Recent Res. Dev. Cell Biochem. 1:2003;207-232.
14. Valkov N.I., Sullivan D.M. Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma. Semin. Hematol. 34:1997;48-68.
15. Larsen A.K., Skladanowski A. Cellular resistance to topoisomerase- targeted drugs: from drug uptake to cell death. Biochim. Biophys. Acta. 1400:1998;257-274.
16. Dalton W.S. Mechanisms of drug resistance in hematologic malignancies. Semin. Hematol. 34:1997;3-8.
17. Sparreboom A., Danesi R., Ando V., Chan J., Figg W.D. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist. Updates. 2:2003;71-84.
18. Allen J.D., Schinkel A.H. Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol. Cancer Ther. 1:2002;427-434.
19. van der Kolk D.M., de Vries E.G., Muller M., Vellenga E. The role of drug efflux pumps in acute myeloid leukemia. Leuk. Lymphoma. 43:2002;685-701.
20. Sullivan D.M., Latham M.D., Ross W.E. Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells. Cancer Res. 47:1987;3973-3979.
21. Yu Q., Mirski S.L., Sparks K.E., Cole S.C. Two COOH-terminal truncated cytoplasmic forms of topoisomerase IIα in a VP-16-selected lung cancer cell line result from partial gene deletion and alternative splicing. Biochemistry. 36:1997;5868-5877.
22. Pommier Y., Fesen M.R., Goldwasser F. Topoisomerase II inhibitors: the epipodophyllotoxins, m-AMSA, and the ellipticine derivatives. Chabner B.A., Longo D.L. Cancer Chemotherapy and Biotherapy. 1996;435-461 Lippincott-Raven Publishers, Philadelphia.
23. Valkov N.I., Gump J.L., Engel R., Sullivan D.M. Cell density-dependent VP-16 sensitivity of leukemic cells is accompanied by the translocation of topo IIα from the nucleus to the cytoplasm. Br. J. Haematol. 108:2000;331-334.
24. Oloumi A., MacPhail S.H., Johnston P.J., Banáth J.P., Olive P.L. Changes in subcellular distribution of topoisomerase IIα correlate with etoposide resistance in multicell spheroids and xenograft tumors. Cancer Res. 60:2000;5747-5753.
25. Burden D.A., Kingma P.S., Froelich-Ammon S.J., Bjornsti M.-A., Patchan M.W., Thompson R.B., Osheroff N. Topoisomerase II*etoposide interactions direct the formation of drug-induced enzyme-DNA cleavage complexes. J. Biol. Chem. 271:1996;29238-29244.
26. Ernst A., Soltermann A., Sigrist J.A., Widmer L., Gasser S.M., Stahel R.A. Ectopic expression of human topoisomerase IIα fragments and etoposide resistance in mammalian cells. Int. J. Cancer. 88:2000;99-107.
27. Austin C.A., Marsh K.L., Wasserman R.A., Wilmore E., Sayer P.J., Wang J.C., Fisher L.M. Expression, domain structure, and enzymatic properties of an active recombinant human DNA topoisomerase IIβ J. Biol. Chem. 270:1995;15739-15746.
28. Hochhauser D., Valkov N.I., Gump J.L., Wei I., O'Hare C., Hartley J., Fan J., Bertino J.R., Banerjee D., Sullivan D.M. Effects of wild-type p53 expression on the quantity and activity of topoisomerase IIα and β in various human cancer cell lines. J. Cell. Biochem. 75:1999;245-257.
29. Beidler D.R., Cheng Y.-C. Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity. Mol. Pharmacol. 47:1995;907-914.
30. Sullivan D.M., Glisson B.S., Hodges P.K., Smallwood-Kentro S., Ross W.E. Proliferation dependence of topo II mediated drug action. Biochemistry. 25:1986;2248-2256.
31. Kaufmann S.H., Svingen P.A., Gore S.T., Armstrong D.K., Cheng Y.C., Rowinsky E.K. Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells. Blood. 89:1997;2098-2104.
32. Kent C.R., Eady J.J., Ross G.M., Steel G.G. The comet moment as a measurement of DNA damage in the comet assay. Int. J. Radiat. Biol. 67:1995;655-660.
33. Tricoli J.V., Sahai B.M., McCormick P.J., Jarlinski S.J., Bertram J.S., Kowalski D. DNA topoisomerase I and II activities during cell proliferation and the cell cycle in cultured mouse embryo fibroblast (C3H 10T/2) cells. Exp. Cell Res. 158:1985;1-14.
34. Hsiang Y.-H., Wu H.-Y., Liu L.F. Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Res. 48:1988;230-3235.
35. Hamamoto T., Gunji S., Tsuji H., Beppu T. Leptomycins A and B, new antifungal antibiotics: III. Mode of action of leptomycin B on Schizosaccharomyces pombe. J. Antibiot. 38:1985;1573-1580.
36. Nishi K., Yoshida M., Fujiwara D., Nishikawa M., Horinouchi S., Beppu T. Leptomycin B targets a regulatory cascade of CRM1, a fission yeast nuclear protein, involved in control of higher order chromosome structure and gene expression. J. Biol. Chem. 269:1994;6320-6324.
37. Kudo N., Wolff B., Sekimoto T., Schreiner E.P., Yoneda Y., Yanagida M., Horinouchi S., Yoshida M. Leptomycin B inhibition of signal-mediated nuclear export by direct binding to CRM1. Exp. Cell Res. 242:1998;540-547.
38. Kudo N., Matsumori N., Taoka H., Fujiwara E., Schreiner P., Wolff B., Yoshida M., Horinouchi S. Leptomycin B inactivates Crm1/exportin by covalent modification at a cysteine residue in the central conserved region. Proc. Natl. Acad. Sci. U. S. A. 96:1999;9112-9117.
39. Hazlehurst L.A., Valkov N.I., Wisner L., Storey J.A., Boulware D., Sullivan D.M., Dalton W.S. Reduction in drug-induced DNA double-strand breaks associated with β1 integrin-mediated adhesion correlates with drug resistance in U937 cells. Blood. 98:2001;1897-1903.
40. Feldhoff P.W., Mirski S.L., Cole S.C., Sullivan D.M. Altered subcellular distribution of topoisomerase IIα in a drug-resistant human small cell lung cancer cell line. Cancer Res. 54:1994;756.
41. Valkov N.I., Gump J.L., Sullivan D.M. Quantitative immunofluorescence and immunoelectron microscopy of the topoisomerase IIα associated with the nuclear matrices from wild-type and drug-resistant Chinese hamster ovary cell lines. J. Cell. Biochem. 67:1997;112-130.
42. Harker G.W., Slade L.D., Parr R.L., Holguin M.H. Selective use of an alternative stop codon and polyadenylation signal within intron sequences leads to a truncated topoisomerase IIα messenger RNA and protein in human HL-60 leukemia cells selected for resistance to mitoxantrone. Cancer Res. 55:1995;4962-4971.
43. 5 tail anchors and stabilizes subdomains of human DNA topoisomerase IIα in the cytoplasm of retrovirally infected mammalian cells. Exp. Cell Res. 248:1999;308-319.